Publications

FTC’s Latest Effort To Dispute Improper Patent Listings Barely Made A Dent

Quoted, Generics Bulletin

Chad Landmon, Chair of Hatch-Waxman and Biologics, discusses the FTC’s latest efforts to challenge improper patent listings and how they have made minimal progress.